Hangzhou, Nov.22,2023 – Hangzhou HealZen Therapeutic, a clinical-stage innovative biotech company providing patients with reliable and novel treatment solutions and improving patient’s living standards aiming at unmet clinical needs, announced that two clinical studies of cell B and T/NK lymphoma from HealZen’s oncology pipeline were selected for presentation at the 65th American Society of Hematology (ASH) Annual Meeting on December 9-12,2023 in San Diego, California, United States.

Poster Presentation 1

Title: A Phase I/II Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BTK Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory Central Nervous System Lymphoma

Abstract Number:3139 

Session Name:627. Aggressive Lymphomas: Clinical and Epidemiological: Poster II

Presentation Time: 6:00 PM - 8:00 PM, Dec.10,2023(Sunday, EST)

Presenting Author: Wenbin Li, Zhuang Kang, Feng Chen, Shenglan Li, Xianggui Yuan, Xi Chen, Wenbin Qian, Haiyan Yang, Miao Hu, Yanping Zhang, Xinglu Zhou

Poster Presentation 2

Title: A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Dual CK1ε/PI3Kδ Inhibitor HZ-H08905 in Adult Patients with Relapsed and/or Refractory Hematologic Malignancies

Abstract Number:4428 

Session Name:624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster III

Presentation Time: 6:00 PM - 8:00 PM, Dec.11,2023(Monday, EST)

Presenting Author: Juying Wei, Wenjuan Yu, Zhengming Jin, Keshu Zhou, Haiyan Yang, Fei Li, Lanfang Li, Miao Hu, Xinglu Zhou, Yanping Zhang, Jie Jin

With more than 18,000 members from nearly 100 countries, ASH is the world's largest professional society serving both clinicians and scientists around the world who are working to conquer blood diseases. The 65th ASH Annual Meeting and Exposition will take place December 9-12,2023, in San Diego, California, and online.